Sébastien Mas – CEO, Skyepharma
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
As dermo-cosmetics inventors, Pierre Fabre Dermo Cosmetics innovates in skin care and hair care fields and solutions following a sacrosanct principle of beauty rooted in ethics.
Backed by a pharmaceutical laboratory, the key to our scientific excellence, Pierre Fabre designs dermo-cosmetic treatments according to the most rigorous criteria for efficacy and safety. At Pierre Farbe, we are focused on acquiring the most cutting-edge expertise and technology, particularly in natural substances, hydrotherapy in dermatology, biotechnologies, and sterile cosmetics.
Recommended by health care professionals, our dermo-cosmetic treatments are administered by staff trained in our beauty ethics approach, thus guaranteeing individually tailored solutions.
As specialists in dermatological therapy with Pierre Fabre Dermatology we are no. 1 in Europe and no. 2 globally on the dermo-cosmetics market, with sales of over €1 billion across 130 countries, and a portfolio of 10 complementary brands.
Pierre Fabre is committed to developing our brands in all parts of the world. Each brand in our portfolio has its own DNA and is positioned to target a different type skin types and needs. Our brands are based on natural active ingredients: thermal spring water for Avène, Rhealba® Oat for A-Derma, plant extracts for Klorane and Elancyl, essential oils and plant extracts for René Furterer. Our dermo-cosmetics products are developed, clinically tested and manufactured according to the standards set out by the pharmaceutical industry.
Contact
Pierre Fabre Dermo-Cosmetics
Les Cauquillous
81506 Lavaur Cedex
+33 149 10 81 68
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
ANSM’s Director General Catherine Paugam-Burtz offers a clear view of how France’s medicines agency is adapting to a fast-shifting landscape. She discusses ANSM’s role within the European regulatory system, the…
Pascaline Gervoson, CEO of PiLeJe, a family-owned French nutraceutical company, represents the second generation of leadership following her father’s founding vision in 1992. With 27 years within the organisation and…
ISISPHARMA’s story unfolds through the Dewavrin group’s evolution from textile manufacturing into a science driven portfolio spanning dermocosmetics and micronutrition. Grégoire Dewavrin explains how the brand has grown through a…
At a time when France’s healthcare landscape is being reshaped by regulatory change, market pressure, and shifting patient expectations, Fabrice Ruggeri, Country Manager of Organon France, is steering the affiliate…
Under the leadership of Nicolas Bardonnet, Promega France has expanded its role from a broad portfolio provider to a more collaborative partner supporting key human health applications. Bardonnet has integrated…
Benta Lyon is reshaping its industrial footprint with unusual speed, combining a fast-growing CDMO platform, an expanding French made generics portfolio and new sterile capabilities that will anchor its next…
argenx has moved from an antibody engineering start-up to one of Europe’s most closely-watched biotechs, advancing a pipeline that spans multiple autoimmune diseases. In this interview, François Rauch reflects on…
With over 25 years of experience at the crossroads of science and business, Pascal Villemagne, CEO of SEQENS, shares his vision for steering the French CDMO into a new era…
France’s territorial landscape is undergoing a profound shift, and departments are emerging as decisive actors in the response to medical deserts, demographic ageing and the widening gaps in prevention and…
Jerome Estampes, CFO and interim CEO of Guerbet France, discusses his journey from joining the company in 2019 through to his current dual role, navigating the challenges of generic competition,…
Alexion France is entering a pivotal phase as the rare-disease landscape becomes more competitive, more data driven and increasingly shaped by early access and clinical-trial performance. In this interview, Celine…
See our Cookie Privacy Policy Here
